Drug intelligence / Profile preview

AMCNP

Development stage: Preclinical
Lead developer: National Cancer Institute
Modality: Nanoparticles → Drug Delivery Systems, Vaccines & Immunotherapeutics
Administration: Subcutaneous

Overview

AMCNP (AML cell membrane-coated nanoparticle) is a cancer vaccine platform designed to prevent relapse after chemotherapy in acute myeloid leukemia (AML) patients. It consists of immune-stimulatory adjuvant-loaded nanoparticles, specifically poly (lactic-co-glycolic acid) (PLGA) cores, coated with leukemic cell membrane material. This design allows for the co-delivery of membrane-associated antigens and adjuvants, such as CpG oligodeoxynucleotide 1826 (a Toll-like receptor 9 agonist), to antigen-presenting cells (APCs), thereby stimulating leukemia-specific immune responses and enhancing T cell expansion and effector function.

Other names: AML cell membrane-coated nanoparticle vaccine

Targets

TLR9 (Toll-like receptor 9)

Beyond the preview

Go deeper on AMCNP.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AMCNP.

Explore the full profile